These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 9689189)

  • 1. Effect of ipriflavone--a synthetic derivative of natural isoflavones--on bone mass loss in the early years after menopause.
    Gennari C; Agnusdei D; Crepaldi G; Isaia G; Mazzuoli G; Ortolani S; Bufalino L; Passeri M
    Menopause; 1998; 5(1):9-15. PubMed ID: 9689189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of chronic treatment with ipriflavone in postmenopausal women with low bone mass.
    Gennari C; Adami S; Agnusdei D; Bufalíno L; Cervetti R; Crepaldi G; Di Marco C; Di Munno O; Fantasia L; Isaia GC; Mazzuoli GF; Ortolani S; Passeri M; Serni U; Vecchiet L
    Calcif Tissue Int; 1997; 61 Suppl 1():S19-22. PubMed ID: 9263612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effect of calcium supplementation on bone loss in perimenopausal women.
    Elders PJ; Lips P; Netelenbos JC; van Ginkel FC; Khoe E; van der Vijgh WJ; van der Stelt PF
    J Bone Miner Res; 1994 Jul; 9(7):963-70. PubMed ID: 7942164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Common biochemical markers of bone turnover predict future bone loss: a 5-year follow-up study.
    Löfman O; Magnusson P; Toss G; Larsson L
    Clin Chim Acta; 2005 Jun; 356(1-2):67-75. PubMed ID: 15936304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.
    Jolly EE; Bjarnason NH; Neven P; Plouffe L; Johnston CC; Watts SD; Arnaud CD; Mason TM; Crans G; Akers R; Draper MW
    Menopause; 2003; 10(4):337-44. PubMed ID: 12851517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic and bone effects after administration of ipriflavone and salmon calcitonin in postmenopausal osteoporosis.
    Cecchettin M; Bellometti S; Cremonesi G; Solimeno LP; Torri G
    Biomed Pharmacother; 1995; 49(10):465-8. PubMed ID: 8746073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between BMD, dental panoramic radiographic findings and biochemical markers of bone turnover in diagnosis of osteoporosis.
    Vlasiadis KZ; Damilakis J; Velegrakis GA; Skouteris CA; Fragouli I; Goumenou A; Matalliotakis J; Koumantakis EE
    Maturitas; 2008 Mar; 59(3):226-33. PubMed ID: 18342460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of bone loss by clodronate in early postmenopausal women with vertebral osteopenia: a dose-finding study.
    Välimäki MJ; Laitinen K; Patronen A; Puolijoki H; Seppänen J; Pylkkänen L; Aranko SM; Sairanen S; Blåfield H; Rekiaro M; Väisänen K; Kormano M; Mäkinen L; Salmi J; Ala-Kaila K; Perttilä J; Vesterinen K; Koivunoro K;
    Osteoporos Int; 2002 Dec; 13(12):937-47. PubMed ID: 12459936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.
    Confavreux CB; Fontana A; Guastalla JP; Munoz F; Brun J; Delmas PD
    Bone; 2007 Sep; 41(3):346-52. PubMed ID: 17618847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in bone markers after once-weekly low-dose alendronate in postmenopausal women with moderate bone loss.
    Choi HJ; Im JA; Kim SH
    Maturitas; 2008 Jun; 60(2):170-6. PubMed ID: 18572334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of ipriflavone administration on bone mass and metabolism in ovariectomized women.
    Gambacciani M; Spinetti A; Cappagli B; Taponeco F; Felipetto R; Parrini D; Cappelli N; Fioretti P
    J Endocrinol Invest; 1993 May; 16(5):333-7. PubMed ID: 8320424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postmenopausal bone loss: does HRT always work?
    Stevenson JC; Hillard TC; Lees B; Whitcroft SI; Ellerington MC; Whitehead MI
    Int J Fertil Menopausal Stud; 1993; 38 Suppl 2():88-91. PubMed ID: 8252111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of isoflavones on lipids and bone turnover markers in menopausal women.
    Schult TM; Ensrud KE; Blackwell T; Ettinger B; Wallace R; Tice JA
    Maturitas; 2004 Jul; 48(3):209-18. PubMed ID: 15207886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ipriflavone prevents radial bone loss in postmenopausal women with low bone mass over 2 years.
    Adami S; Bufalino L; Cervetti R; Di Marco C; Di Munno O; Fantasia L; Isaia GC; Serni U; Vecchiet L; Passeri M
    Osteoporos Int; 1997; 7(2):119-25. PubMed ID: 9166391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ipriflavone in the treatment of postmenopausal osteoporosis: a randomized controlled trial.
    Alexandersen P; Toussaint A; Christiansen C; Devogelaer JP; Roux C; Fechtenbaum J; Gennari C; Reginster JY;
    JAMA; 2001 Mar; 285(11):1482-8. PubMed ID: 11255425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of ipriflavone in established osteoporosis and long-term safety.
    Agnusdei D; Bufalino L
    Calcif Tissue Int; 1997; 61 Suppl 1():S23-7. PubMed ID: 9263613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17.
    Perez EA; Josse RG; Pritchard KI; Ingle JN; Martino S; Findlay BP; Shenkier TN; Tozer RG; Palmer MJ; Shepherd LE; Liu S; Tu D; Goss PE
    J Clin Oncol; 2006 Aug; 24(22):3629-35. PubMed ID: 16822845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of continuous oestradiol with intermittent norgestimate on bone mineral density and bone turnover in post-menopausal women.
    Arrenbrecht S; Caubel P; Garnero P; Felsenberg D
    Maturitas; 2004 Jul; 48(3):197-207. PubMed ID: 15207885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A double blind, placebo-controlled trial of ipriflavone for prevention of postmenopausal spinal bone loss.
    Agnusdei D; Crepaldi G; Isaia G; Mazzuoli G; Ortolani S; Passeri M; Bufalino L; Gennari C
    Calcif Tissue Int; 1997 Aug; 61(2):142-7. PubMed ID: 9236262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss.
    Reginster JY; Deroisy R; Lecart MP; Sarlet N; Zegels B; Jupsin I; de Longueville M; Franchimont P
    Am J Med; 1995 May; 98(5):452-8. PubMed ID: 7733123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.